Table 1 BAL/serum cytokine concentrations (pg/mL) in RSV infected mice treated with motavizumab compared with untreated RSV infected controls on day 1 after inoculation. Each group consisted of 4 samples randomly selected from two independent experiments.
BAL (D1) | SERUM (D1) | |||||
|---|---|---|---|---|---|---|
RSV Untreated | RSV Motavizumab | p value | RSV Untreated | RSV motavizumab | p value | |
IFN-γ | 67.16 ± (24.6) | 28.01 ± (13.8) | 0.03 | ND | ND | --- |
MCP-1 | 1930.68 ± (716.6) | 1088.12 ± (307.8) | 0.07 | 381.83 (341.0–554.8) | 230.65 (217.43–298.83) | 0.6 |
RANTES | 1952.10 ± (999.05) | 671.66 ± (340.4) | 0.051 | ND | ND | --- |
IL-10 | 39.29 ± (27.0) | 14.47 ± (7.8) | 0.1 | 102.23 ± (22.5) | 16.78 ± (13.56) | 0.001 |
TNF-α | 2290.90 ± (1100.2) | 279.03 ± (204.7) | 0.01 | ND | ND | --- |
GM-CSF | 101.42 (45.7–144.9) | 25.14 (22.1–34.0) | 0.1 | ND | ND | --- |
IL-12p70 | 44.14 ± (13.5) | 22.59 ± (8.7) | 0.03 | 45.85 ± (17.5) | 23.75 ± (16.1) | 0.16 |
KC | 3967.43 (2039.8–5795.3) | 1303.57 (946.4–1657.1) | 0.1 | 215.86 ± (125.8) | 37.63 ± (32.5) | 0.03 |
IL-6 | 2580.89 ± (1413.6) | 821.79 ± (290.13) | 0.051 | 91.39 (45.43–135.31) | 31.17 (18.97–35.85) | 0.2 |
IL-1β | 477.52 (231.53–831.92) | 182.78 (179.4–214.3) | 0.3 | 266.88 ± (74.4) | 119.70 ± (143.5) | 0.16 |
IL-1α | 289.75 ± (114.0) | 76.28 ± (29.1) | 0.01 | ND | ND | --- |
IL-17 | ND | ND | --- | 20.68 (11.94–31.85) | 10.67 (10.06–12.03) | 0.2 |